NasdaqGS - Nasdaq Real Time Price USD

Certara, Inc. (CERT)

Compare

9.73

+0.68

+(7.51%)

At close: April 9 at 4:00:03 PM EDT

9.92

+0.19

+(1.95%)

After hours: April 9 at 4:25:02 PM EDT

Certara Expands the Simcyp™ Simulator Platform Advancing Biopharmaceutics, Drug-Drug Interaction & Biologic Capabilities

Updates strengthen Certara’s position as a leader of PBPK modeling in drug development to advance regulatory decision-makingRADNOR, Pa., April 01, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, has released a new version of the Simcyp™ Simulator for physiologically-based pharmacokinetic (PBPK) modeling. Simcyp PBPK models describe and predict the behavior of drugs in different body tissues. The latest version includes numerous advanceme

GlobeNewswire 8 days ago

CERT
+7.51%
At US$9.91, Is Certara, Inc. (NASDAQ:CERT) Worth Looking At Closely?

Certara, Inc. ( NASDAQ:CERT ), is not the largest company out there, but it saw significant share price movement during...

Simply Wall St. 11 days ago

CERT
+7.51%
Arvinas (ARVN) Moves 8.8% Higher: Will This Strength Last?

Arvinas (ARVN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks 27 days ago

ARVN

CERT
+7.51%
Certara, Inc. (CERT): Among the Cash-Rich Small Cap Stocks To Invest In According To Analysts

We recently compiled a list of the 10 Cash-Rich Small Cap Stocks To Invest In According To Analysts. In this article, we are going to take a look at where Certara, Inc. (NASDAQ:CERT) stands against the other cash-rich small cap stocks. Small-cap stocks in the US have been under pressure, with the Russell small cap index […]

Insider Monkey last month

CERT
+7.51%
Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions

McKemey joins Certara to accelerate growth of its strategic drug development solutionsRADNOR, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of Adrian McKemey, Ph.D. as President of Drug Development Solutions, effective March 3rd, 2025. In this role, McKemey will lead Certara's global team of drug development scientists. Adrian joins Certara after serving as head of Enterprise Transformatio

GlobeNewswire last month

CERT
+7.51%
Q4 2024 Certara Inc Earnings Call

Q4 2024 Certara Inc Earnings Call

Thomson Reuters StreetEvents last month

CERT
+7.51%
Certara Inc (CERT) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansions

Certara Inc (CERT) reports a robust 14% increase in fourth-quarter revenue, driven by software growth and strategic acquisitions, while navigating market challenges.

GuruFocus.com last month

CERT
+7.51%
Certara, Inc. (CERT) Surpasses Q4 Earnings and Revenue Estimates

Certara (CERT) delivered earnings and revenue surprises of 15.38% and 0.68%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

CERT
+7.51%
Certara Reports Fourth Quarter 2024 Financial Results

Issues Full Year 2025 Financial GuidanceRADNOR, Pa., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the fourth quarter and full year 2024. Fourth Quarter Highlights: Revenue was $100.4 million, compared to $88.0 million in the fourth quarter of 2023, representing growth of 14%. Software revenue was $42.3 million, compared to $33.6 million in the fourth quarter of 2023, representing growt

GlobeNewswire last month

CERT
+7.51%
HPQ Set to Report Q1 Earnings: What's in the Cards for the Stock?

HP's first-quarter 2025 results are likely to reflect gains from traction in its AI-based computing and latest gaming products.

Zacks last month

HPQ

MRVL

CERT
+7.51%
Certara, Inc. (CERT): Among the Health Information Services Stocks Outpacing the Market in 2025

We recently published an article titled Top 10 Health Information Services Stocks Outpacing The Market In 2025. In this article, we are going to take a look at where Certara, Inc. (NASDAQ:CERT) stands against the other health information services stocks. Health Information Services stocks have become a key focus for investors as AI starts to enter […]

Insider Monkey last month

CERT
+7.51%
^GSPC
Has BioRad Laboratories (BIO) Outpaced Other Medical Stocks This Year?

Here is how Bio-Rad Laboratories (BIO) and Certara, Inc. (CERT) have performed compared to their sector so far this year.

Zacks 2 months ago

BIO-B

CERT
+7.51%
Certara to Report Fourth Quarter and Full Year 2024 Financial Results on February 26th, 2025 and Participate in Upcoming Investor Conferences

RADNOR, Pa., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the fourth quarter and full year of 2024 after the market close on Wednesday, February 26th, 2025. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at

GlobeNewswire 2 months ago

CERT
+7.51%
Certara Inc. (CERT): Accelerating Drug Development with AI Amid Leerink’s Target Price Boost to $13

We recently compiled a list of the Top 10 Medical AI Stocks on Wall Street’s Radar. In this article, we are going to take a look at where Certara Inc. (NASDAQ:CERT) stands against the other medical AI stocks. Investments in the global healthcare industry have ramped up sharply since the COVID-19 pandemic. With the advent of […]

Insider Monkey 2 months ago

CERT
+7.51%
Exploring High Growth Tech Stocks in January 2025

The United States market has shown robust performance with a 3.8% climb over the past week and a substantial 24% increase over the last year, while earnings are anticipated to grow by 15% annually in the coming years. In this context of strong market momentum, identifying high growth tech stocks involves looking for companies with innovative technologies and scalable business models that can capitalize on these favorable economic conditions.

Simply Wall St. 2 months ago

CERT
+7.51%
RYTM

VCYT
Certara Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results

Full-Year 2024 Revenue of $384.4 million, Bookings of $445.3 millionConfirms Adjusted EBITDA within Guidance Range of $120 million to $124 million RADNOR, Pa., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced revenue and bookings for the fourth quarter and full year of fiscal year 2024 based on a preliminary review of fourth quarter results. Preliminary financials for the fourth quarter of 2024 are expected to be

GlobeNewswire 2 months ago

CERT
+7.51%
Certara (NASDAQ:CERT) Will Be Hoping To Turn Its Returns On Capital Around

To find a multi-bagger stock, what are the underlying trends we should look for in a business? Ideally, a business will...

Simply Wall St. 2 months ago

CERT
+7.51%
Cautious Spending By Large Biopharma Client Dragged Certara (CERT) in Q3

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” third-quarter 2024 investor letter. A copy of the letter can be downloaded here. In the quarter the fund returned 6.50% (gross) and 6.24% (net), compared to an 8.41% return for the Russell 2000 Growth Index. Global markets performed fairly in […]

Insider Monkey 4 months ago

CERT
+7.51%
Certara Showcases 2024 Research Wins With Over 100 Papers Published

The company celebrates the 12 scientists included in the Stanford/Elsevier top 2% cited researchers listRADNOR, Pa., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today showcases its impact on research by celebrating more than 100 publications secured in 2024 as well as the 12 Certara scientists included on the 2024 Stanford/Elsevier list, which highlights the top 2% of the most cited scientists across the globe. Stanford/Else

GlobeNewswire 4 months ago

CERT
+7.51%
Exploring Three High Growth Tech Stocks In The United States

The United States market has shown impressive momentum, climbing 1.6% in the last seven days and 32% over the past year, with earnings forecasted to grow by 15% annually. In such a dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and robust financial health to capitalize on these favorable conditions.

Simply Wall St. 4 months ago

EVH

GDS

CERT
+7.51%

Performance Overview

Return	CERT	S&P 500 (^GSPC)
YTD	-8.64%	-7.22%
1-Year	-47.43%	+4.74%
3-Year	-53.44%	+21.58%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Certara, Inc. (CERT)

Certara Expands the Simcyp™ Simulator Platform Advancing Biopharmaceutics, Drug-Drug Interaction & Biologic Capabilities

At US$9.91, Is Certara, Inc. (NASDAQ:CERT) Worth Looking At Closely?

Arvinas (ARVN) Moves 8.8% Higher: Will This Strength Last?

Certara, Inc. (CERT): Among the Cash-Rich Small Cap Stocks To Invest In According To Analysts

Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions

Q4 2024 Certara Inc Earnings Call

Certara Inc (CERT) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansions

Certara, Inc. (CERT) Surpasses Q4 Earnings and Revenue Estimates

Certara Reports Fourth Quarter 2024 Financial Results

HPQ Set to Report Q1 Earnings: What's in the Cards for the Stock?

Certara, Inc. (CERT): Among the Health Information Services Stocks Outpacing the Market in 2025

Has BioRad Laboratories (BIO) Outpaced Other Medical Stocks This Year?

Certara to Report Fourth Quarter and Full Year 2024 Financial Results on February 26th, 2025 and Participate in Upcoming Investor Conferences

Certara Inc. (CERT): Accelerating Drug Development with AI Amid Leerink’s Target Price Boost to $13

Exploring High Growth Tech Stocks in January 2025

Certara Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results

Certara (NASDAQ:CERT) Will Be Hoping To Turn Its Returns On Capital Around

Cautious Spending By Large Biopharma Client Dragged Certara (CERT) in Q3

Certara Showcases 2024 Research Wins With Over 100 Papers Published

Exploring Three High Growth Tech Stocks In The United States

Performance Overview